Anixa Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-1.2%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$0.31next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| FY 2026 Annual Earnings Release (Fiscal Period Ending October 31, 2026) | 12 Jan 2027 |
Monitoring Framework
Key Performance Indicators
Ovarian Cancer CAR-T (Lira-cel) Phase 1 Patient Survival Observations QuarterlyTarget: Demonstrate extended survival and safety in heavily pretreated patients
Breast Cancer Vaccine Phase 1 Protocol-Defined Immune Response Rate Annually7,400.0%Target: 74% or higher in clinical trials
Cash and Cash Equivalents Quarterly1.5MTarget: Maintain sufficient runway for Phase 2 clinical preparations
Watch Items
- Phase 2 Breast Cancer Vaccine Trial InitiationTrigger: cGMP clinical material manufacturing completion by Cytovance BiologicsAction: Review protocol design, regulatory approvals, and patient enrollment milestones
- Lira-cel Ovarian Cancer CAR-T Dose EscalationTrigger: Regulatory approval for substantial dose escalationAction: Monitor safety profiles and therapeutic efficacy at higher dose cohorts
Research as of 20 Jun 2026